/ -- Under the terms of the agreement, Glenmark will be responsible to manufacture and supply Ryaltris, while Grandpharma will be responsible for regulatory filing and commercialization of Ryaltris in China Glenmark will receive an upfront payment, regulatory filing, regulatory approval and commercial milestone payments as well as royalties from Grandpharma for Ryaltris Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Grandpharma (China) Co. Ltd. (Grandpharma) for commercializing its novel nasal spray Ryaltris in China.
(Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg )
About Glenmark Pharmaceuticals
Disclaimer: No Business Standard Journalist was involved in creation of this content